The Treatment of Advanced Thyroid Cancer Using Pemetrexed Monotherapy or with Platinum-Based Chemotherapy
Authors' conclusion
Pemetrexed single agent or in combination with carboplatin has comparable efficacy to approved second-line therapies for advanced thyroid cancer.
Study context
- Population
- Advanced radioiodine refractory differentiated thyroid cancer and anaplastic thyroid cancer (ATC), Memorial Sloan Kettering Cancer Center, December 2023–December 2025; 11 with ATC, 68% females, 95% with distant metastatic disease11 with ATC
- Participants
- 22 participants
- Exposure
- Pemetrexed monotherapy or with carboplatin
- Pemetrexed ± carboplatinn = 22
- Outcome
- Best overall response
Methodological detailssingle-centre, Median treatment duration about 5 months; median time to pemetrexed initiation 73 months, One patient with ATC remains on pemetrexed/carboplatin with a partial response (PR)
- Single-centre
- Median treatment duration about 5 months; median time to pemetrexed initiation 73 months
- One patient with ATC remains on pemetrexed/carboplatin with a PR
Main finding
As reported in the abstract
Best overall response: partial response (PR)
All patients
27%
6/22 events
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Values |
|---|---|
| Partial response (PR), non-ATC subgroup | Non-ATC 45% |
| Progression-free survival | All tumors median 148 days · Non-ATC median 375 days |
Ongoing response in ATC
- One patient with ATC remains on pemetrexed/carboplatin with a PR to therapy
- 1
Original publication
The Treatment of Advanced Thyroid Cancer Using Pemetrexed Monotherapy or with Platinum-Based Chemotherapy. Thyroid. Published 29 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →